Furlong, Fiona <br/><br/>
Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.  [electronic resource] 

 -  The Journal of pathology  Apr 2012 
 - 746-55 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1096-9896 
<br/><br/><label>Standard No.: </label>10.1002/path.3035  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>3' Untranslated Regions<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Biomarkers, Tumor--genetics<br/>Calcium-Binding Proteins--genetics<br/>Carboplatin--administration & dosage<br/>Carcinoma, Ovarian Epithelial<br/>Cell Cycle Proteins--genetics<br/>Cell Line, Tumor<br/>Chemotherapy, Adjuvant<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Down-Regulation<br/>Drug Resistance, Neoplasm--genetics<br/>Female<br/>Humans<br/>Immunohistochemistry<br/>Kaplan-Meier Estimate<br/>Mad2 Proteins<br/>MicroRNAs--metabolism<br/>Multivariate Analysis<br/>Neoplasm Grading<br/>Neoplasm Staging<br/>Neoplasms, Cystic, Mucinous, and Serous--genetics<br/>Neoplasms, Glandular and Epithelial--drug therapy<br/>Ovarian Neoplasms--drug therapy<br/>Paclitaxel--administration & dosage<br/>Paraffin Embedding<br/>Proportional Hazards Models<br/>RNA Interference<br/>Repressor Proteins--genetics<br/>Retrospective Studies<br/>Risk Assessment<br/>Risk Factors<br/>Time Factors<br/>Transfection<br/>Treatment Outcome